Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:FMTX NASDAQ:PCVX NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.44-2.8%$2.38$0.91▼$5.09$204.25M2.153.01 million shs1.62 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsPCVXVaxcyte$33.02-2.7%$34.43$27.66▼$121.06$4.26B1.191.80 million shs1.11 million shsSRRKScholar Rock$36.36-1.9%$35.14$6.76▼$46.98$3.45B0.331.18 million shs1.42 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-0.40%-23.01%+11.56%+53.05%-53.60%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%PCVXVaxcyte-2.50%-6.32%+3.07%-4.07%-56.97%SRRKScholar Rock-2.06%-5.27%+9.75%+12.58%+308.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.0553 of 5 stars3.23.00.04.32.12.50.6FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.3937 of 5 stars3.62.00.00.03.51.70.0SRRKScholar Rock3.7948 of 5 stars2.61.00.04.43.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.31Hold$4.7092.62% UpsideFMTXForma Therapeutics 0.00N/AN/AN/APCVXVaxcyte 3.10Buy$136.50313.39% UpsideSRRKScholar Rock 3.22Buy$44.1421.40% UpsideCurrent Analyst Ratings BreakdownLatest PCVX, FMTX, SRRK, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetStrong-Buy$53.007/17/2025SRRKScholar RockCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00(Data available from 8/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M6.32N/AN/A$1.63 per share1.50FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ASRRKScholar RockN/AN/AN/AN/A$3.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/APCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest PCVX, FMTX, SRRK, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EDITEditas Medicine-$0.40N/AN/AN/A$1.81 millionN/A8/6/2025Q2 2025SRRKScholar Rock-$0.68N/AN/AN/AN/AN/A8/5/2025Q2 2025PCVXVaxcyte-$1.12N/AN/AN/AN/AN/A5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.083.08FMTXForma TherapeuticsN/A12.7412.74PCVXVaxcyteN/A17.7017.70SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FMTXForma Therapeutics87.39%PCVXVaxcyte96.78%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine2.10%FMTXForma Therapeutics5.79%PCVXVaxcyte3.10%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million81.96 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionablePCVXVaxcyte160129.00 million125.01 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionablePCVX, FMTX, SRRK, and EDIT HeadlinesRecent News About These CompaniesTD Asset Management Inc Sells 23,794 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)August 1 at 7:10 AM | marketbeat.comScholar Rock (SRRK) Expected to Announce Earnings on WednesdayJuly 31 at 10:48 AM | marketbeat.comScholar Rock (NASDAQ:SRRK) Now Covered by Raymond James FinancialJuly 31 at 9:35 AM | marketbeat.comVictory Capital Management Inc. Buys 43,981 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)July 31 at 6:22 AM | marketbeat.comDirector Sells 11,136 Shares of SRRK, a Stock Up 330% in Past YearJuly 24, 2025 | fool.comBank of New York Mellon Corp Has $6.95 Million Stake in Scholar Rock Holding Corporation (NASDAQ:SRRK)July 24, 2025 | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 72,236 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)July 22, 2025 | marketbeat.comCantor Fitzgerald Weighs in on Scholar Rock FY2025 EarningsJuly 22, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts Scholar Rock FY2025 EarningsJuly 21, 2025 | marketbeat.comInsider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 11,136 Shares of StockJuly 19, 2025 | marketbeat.comJeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) StockJuly 19, 2025 | insidertrades.comCantor Fitzgerald Initiates Coverage of Scholar Rock Holding (SRRK) with Overweight RecommendationJuly 18, 2025 | msn.comScholar Rock (NASDAQ:SRRK) Now Covered by Analysts at Cantor FitzgeraldJuly 17, 2025 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of "Buy" from BrokeragesJuly 16, 2025 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Insider Sells $828,833.04 in StockJuly 10, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Trading 6.5% Higher - Should You Buy?July 9, 2025 | marketbeat.comScholar Rock Holding Corporation (SRRK) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comScholar Rock Holding Corp. (SRRK) Stock Price Today - WSJJune 24, 2025 | wsj.comScholar Rock Holding Corp News (SRRK) - Investing.comJune 24, 2025 | investing.comScholar Rock CEO on its drug that could preserve muscle in weight-loss drug usersJune 24, 2025 | youtube.comYScholar Rock: EMBRAZE Results Drive The Stock HigherJune 23, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCVX, FMTX, SRRK, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$2.44 -0.07 (-2.79%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.02 (+1.02%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Vaxcyte NASDAQ:PCVX$33.02 -0.93 (-2.74%) Closing price 04:00 PM EasternExtended Trading$32.91 -0.11 (-0.33%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Scholar Rock NASDAQ:SRRK$36.36 -0.69 (-1.86%) Closing price 04:00 PM EasternExtended Trading$36.36 +0.01 (+0.01%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
